Drug firm in €3.5bn drop

Shares in AstraZeneca fell more than 5%, stripping at one stage €3.5bn from its market value, after the drug company declined to deny a media report that chief executive Pascal Soriot was about to defect to Israel-based Teva Pharmaceutical.

Mr Soriot, who has led the Anglo-Swedish company since 2012, met with Teva’s search committee and its chairman to express his agreement to serve as its next CEO, the Calcalist financial news website reported.

Both companies said they did not comment on market rumours. Teva was left without a permanent CEO in February after Erez Vigodman stepped down.

Moving to a generics drugmaker, albeit the world’s largest, would be a big change in direction for French-born Mr Soriot, 58. During his five years at the company he successfully defended Astra against a €103bn takeover approach from Pfizer.

Mr Soriot is now waiting for all-important data from a Mystic trial of a lung cancer candidate, which Goldman Sachs has said will be one of the year’s most important clinical readouts.


More in this Section

US rate fears crash party

No surprise if airlines collapse as winter sets in

Little drama and little joy from today’s budget

Breaking Stories

Starbucks scales backs European presence but consolidates in London

Leo Varadkar: Cut Brexit deal now or risk economic damage

Finance director challenges Cork employer who says she is 'deemed to have resigned'

Paris seeks to attract London's City workers with new English school after Brexit

Breaking Stories

David Beckham admits marriage is ‘hard work’: Is it normal for long-term relationships to be tough?

On World Menopause Day: 5 myths you really need to stop believing

Photography awards capture life at its wildest

This is how to stay healthy as a new parent – according to The Body Coach

More From The Irish Examiner